Article Text

Download PDFPDF
Gemtuzumab-ozogamicin and blinatumomab as treatment for refractory mixed-phenotype blast crisis in chronic myeloid leukaemia
  1. Roberto Ovilla-Martinez1,
  2. Luis Alejandro Weber Sánchez1,2,
  3. Xóchitl Cota-Rangel1 and
  4. Pamela Elena Baez-Islas1
  1. 1Hematology Department, Hospital Angeles Lomas, Huixquilucan, Estado de Mexico, Mexico
  2. 2Surgery Department, Hospital Angeles Lomas, Huixquilucan, Estado de Mexico, Mexico
  1. Correspondence to Dr Pamela Elena Baez-Islas; drabaez.hematologia{at}


In the tyrosine kinase inhibitor era, the blast phase of chronic myeloid leukaemia (BP-CML) renders an uncommon presentation and has a poor prognosis with an estimated overall survival below 20%. Mixed-phenotype blast phase is even more infrequent, presenting in 3.3% of these patients. Blast phase manifests along haematological sarcomas, with extramedullary activity in lymph nodes, skin and bone. We report the case of a patient with an ovarian sarcoma as an extramedullary presentation of mixed-phenotype BP-CML refractory to conventional treatment which responded to immunotherapy against CD33 and CD19.

  • cancer - see oncology
  • chronic myeloid leukaemia
  • haematology (drugs and medicines)
  • haematology (incl blood transfusion)

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors RO-M, XC-R and PEB-I were responsible for the hemato-oncological treatment of the patient. LAWS was responsible for the surgical treatment of the patient. The original idea was conceived by RO-M. The text was written by PEB-I. The images were provided by LAWS. All authors contributed to the investigation and discussion of the case.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.